-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The strong graft anti-tumor (GVT) effect associated with graft anti-host disease (GVHD) may depend on the type and status of the blood disease.
, however, there is limited data on the effects of GVHD on transplant prognostics in patients with bone marrow prosplation syndrome (MDS).
Konuma and others retrospectively assessed the effects of acute and chronic GVHD on transplant prognosis in adult patients with a large number of low-risk (n-193) and high-risk (n-1926) MDS transplantation treatments between 2001 and 2017.
multivariable analysis showed that in patients with low-risk MDS, the grade or severity of acute and chronic GVHD had no significant effect on total mortality, recurrence rate, or non-mortality (NRM).
for high-risk MDS patients, the development of restrictive chronic GVHD was significantly associated with lower overall mortality (HR 0.66; 95% CI 0.50 to 0.86; P=0.002).
this may be due to a reduced risk of recurrence of class III-IV acute GVHD in high-risk MDS patients, or a limited or widespread increase in chronic GVHD by an increase in NRM in III-IV acute GVHD or widespread chronic GVHD.
study data show that only high-risk MDS patients with restrictive chronic GVHD can obtain the survival benefits of the transplant's anti-MDS effect.
.
